A further investigation of the PIK3CD-S and PIK3CD-L expression profiles in CLL and NHL patients may facilitate our understanding of the mechanisms conferring Idelalisib resistance (other than the IGF1R- and MAP2K1 mutation-mediated MAPK/ERK activation). This evidence concerns the gene IGF1R and B-cell chronic lymphocytic leukemia.